Introduction
Although a decrease is seen in the mortality rate with the widespread of primary percutaneous coronary intervention (p-PCI) in patients with ST-elevation myocardial infarction (STEMI), there is still a high rate of mortality1. The rapid and successful revascularization of the infarct-related artery (IRA) has proven to be the most effective treatment option in patients with STEMI and improves clinical outcomes. IRA patency before p-PCI cause the short duration of ischemia in STEMI patients, thus decreasing complications such as infarction-related heart failure, cardiogenic shock and mortality, and high procedure success2.
The use of inflammatory biomarkers has been increasing in the diagnosis and screening of atherosclerotic heart disease (AHD)3. Among the most frequently used biomarkers for this purpose, C-reactive protein (CRP) and albumin are known to have a strong association with individual AHD formation and presentation forms.4,5C-reactive protein/Albumin ratio (CAR) reflects the stability of albumin and CRP levels in the body. It has been shown to reflect the inflammatory status and prognosis better than the hs-CRP or albumin alone in critical patients, acute medical conditions, and cancer patients6-9.
Detection of IRA patency in p-PCI in patients with STEMI provides predicting mortality and morbidity rates of the patients10. Therefore, in the present study, it was aimed to investigate the relationship between IRA patency before p-PCI and CAR in patients with STEMI.